Comments
Mangalam Drugs and Organics on Monday said that it recently received the final approval from World Health Organisation (WHO) for the drug Efavirenz, which is used in the treatment of HIV/AIDS. It is generally recommended for use with other anti-retrovirals. For the quarter ended June 2018, Mangalam Drug has reported a profit of ₹67 lakh on revenues of ₹59.01 crore; for FY18, the company had posted a PAT of ₹19.89 crore on revenues of ₹279.38 crore.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.